Why shares of Novavax crashed 37.7% in May

Delays frustrated investors.

| More on:
disappointed and sad woman

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of coronavirus vaccine maker Novavax (NASDAQ: NVAX) tanked by 37.7% in May, according to data provided by S&P Global Market Intelligence. The collapse was a result of the company's repeated delays with the manufacturing of its coronavirus vaccine as well as its announcement that it won't file for the candidate's regulatory approval before the third quarter.

So what

The combination of delays with regulatory filings and manufacturing delays means that Novavax won't be able to deliver its contractually obligated doses to the European Union before 2022. In short, certain raw materials needed for the vaccine are in scant supply. Furthermore, the company will be even further behind other vaccine makers like Pfizer and Moderna, which are already on the market and in wide distribution.

In the long run, however, these issues probably won't harm the company's revenue making potential. Even amid the delays, Novavax is still signing new sales agreements with groups like the Gavi Vaccine Alliance, which agreed to buy 350 million doses of its vaccine on May 6. Likewise, Novavax still has commitments to make more than 1.1 billion doses in conjunction with its manufacturing collaborators. So, while May's losses might be frustrating, they probably don't reflect much genuine destruction of shareholder value. It's likely that the stock will rebound once sales revenue starts to be reflected in earnings reports.

Now what

While investors are unlikely to have much patience for further delays, Novavax is still proceeding with its plans to commercialize its coronavirus vaccine globally, and it will almost certainly continue to succeed in doing so. Notably, in early May it also reported that its candidate is effective against at least one viral variant, which should keep it competitive with the currently marketed vaccines. But shareholders will need to wait a bit longer before the full impact of the revenue is reflected in the company's quarterly earnings reports.

Beyond that, the company is also pursuing its combination vaccine project, which could inoculate people against both influenza and the coronavirus in a single jab. On May 10, it published preliminary evidence from preclinical studies that suggests the combination vaccine could be effective.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Is Nvidia a Buy?

Here's a look at Nvidia's latest quarterly earnings and management's outlook.

Read more »

A tech worker wearing a mask holds computer chip up to the camera.
International Stock News

Is Nvidia Stock a Buy Now?

Nvidia (NASDAQ: NVDA) may be the most watched stock in the market.

Read more »

A woman shrugs and pulls awkward expression with her face.
International Stock News

Amazon Stock: Buy, Hold or Sell?

Amazon has the ingredients to keep growing for a while.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
International Stock News

Prediction: This Artificial Intelligence (AI) Company Will Be Worth Over $5 Trillion in 10 Years

Investors should not let the short-term noise distract them from the company's long-term growth prospects.

Read more »

Woman sits at computer in a quandary with hands at side of head
International Stock News

Will Apple Reclaim Its Title as the Largest Company in the World by Market Cap? The Answer May Surprise You.

For more than a decade, Apple (NASDAQ: AAPL) was the largest company in the world by market capitalization.

Read more »

Man smiling at a laptop because of a rising share price.
International Stock News

Which 2 'Magnificent 7' companies soared 23% and 24% in May?

May was kind to these tech giants.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Nvidia CEO Jensen Huang just delivered incredible news for Amazon investors

Nvidia's strong results and investments in its product line are good news for Jassy and Amazon.

Read more »

Elderly woman teaching a younger woman using fruit, comparing apples with apples.
International Stock News

Apple stock: Did President Trump just give investors a reason to sell?

Let's take a look.

Read more »